<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37698062</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Examination of autoantibodies to type I interferon in patients suffering from long COVID.</ArticleTitle><Pagination><StartPage>e29089</StartPage><MedlinePgn>e29089</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29089</ELocationID><Abstract><AbstractText>Long COVID (LC) is an emerging global health concern. The underlying mechanism and pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 interferons (IFN) has been established as a predictor of critical COVID-19. We hypothesized that persistent autoimmune activity with autoantibodies against type 1 IFN may contribute to symptoms in patients with LC. Plasma samples and clinical information were obtained from a Danish LC cohort consisting of adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Information on symptoms and quality of life was derived from an LC-specific questionnaire and the EQ-5D-5L questionnaire. Detection of type 1 IFN autoantibodies in plasma were performed by ELISA. Samples collected between June, 2020, and September, 2021, from 279 patients were analyzed and compared to a control group of 94 individuals with prior mild SARS-CoV-2 infection who did not develop LC symptoms. In total, five LC patients (1.8%) and 3 (3.2%) of the controls had detectable circulating type 1 IFN autoantibodies. Collectively, prevalence of autoantibodies against type 1 IFN subtypes in our LC cohort were primarily driven by men and did not exceed the prevalence in controls. Thus, in our cohort, anti-type I IFN autoantibodies are unlikely to drive LC symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Kristoffer Skaalum</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0002-0902-352X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf8;rgensen</LastName><ForeName>Sofie Eg</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skouboe</LastName><ForeName>Morten Kelder</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-9358-5500</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agergaard</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schi&#xf8;ttz-Christensen</LastName><ForeName>Berit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of General Practice, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vibholm</LastName><ForeName>Line Khalidan</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolstrup</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd8;stergaard</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leth</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases &amp; Internal Medicine, G&#xf8;dstrup Regional Hospital, Herning, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mogensen</LastName><ForeName>Trine H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37698062</ArticleId><ArticleId IdType="doi">10.1002/jmv.29089</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Med. 2021;27(4):601-615.</Citation></Reference><Reference><Citation>McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87-103.</Citation></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036-1045.</Citation></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.</Citation></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.</Citation></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.</Citation></Reference><Reference><Citation>Soltani-Zangbar MS, Parhizkar F, Ghaedi E, et al. A comprehensive evaluation of the immune system response and type-I interferon signaling pathway in hospitalized COVID-19 patients. Cell Commun Signaling. 2022;20(1):106.</Citation></Reference><Reference><Citation>World Health Organization. Post COVID-19 condition. Accessed February 2, 2023. https://www.who.int/teams/health-care-readiness/post-covid-19-condition</Citation></Reference><Reference><Citation>Nielsen SS, Vibholm LK, Monrad I, et al. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine. 2021;68:103410.</Citation></Reference><Reference><Citation>Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-&#x3b3;. J Clin Invest. 2005;115(9):2480-2488.</Citation></Reference><Reference><Citation>H&#xf6;flich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-&#x3b3; autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood. 2004;103(2):673-675.</Citation></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.</Citation></Reference><Reference><Citation>Peluso MJ, Mitchell A, Wang CY, et al. Low prevalence of Interferon-&#x3b1; autoantibodies in people experiencing long COVID symptoms. J Infect Dis. 2022;227(2):246-250.</Citation></Reference><Reference><Citation>Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. Sci Immunol. 2022;7(67):eabm5505.</Citation></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.</Citation></Reference><Reference><Citation>FAIR Health. Releases study on post-COVID conditions. Accessed August 4, 2023. https://www.fairhealth.org/article/fair-health-releases-study-on-post-covid-conditions</Citation></Reference><Reference><Citation>Chen TH, Chang CJ, Hung PH. Possible pathogenesis and prevention of long COVID: SARS-CoV-2-Induced mitochondrial disorder. Int J Mol Sci. 2023;24(9):8034.</Citation></Reference><Reference><Citation>Shaw ER, Rosen LB, Cheng A, et al. Temporal dynamics of Anti-Type 1 interferon autoantibodies in patients with coronavirus disease 2019. Clin Infect Dis. 2022;75(1):e1192-e1194.</Citation></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575-578.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>